Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.
7 reports, 5 independent
Updated Aug 16
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 7
- Developments
- 4
- Repetition
- 43%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Market share gains and clinical failures complicate the competitive landscape in ATTR-CM.1 source
Rival company gaining momentum in ATTR-CM market.1 source
Stifel analyst commented on AstraZeneca's drug development in the ATTR-CM market.1 source
Alnylam and BridgeBio expand market presence in EU; Pfizer competes in ATTR-CM.1 source
Keep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
BridgeBio
company in Palo Alto, United States
Related events
- FDA and Pfizer are seeking regulatory approval for their products.
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
- Pfizer is jointly marketing the drug Eliquis.
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.
- Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.
Coverage
Newest first; wire copies grouped- yahoo.com
- fool.com
- biopharmadive.com
- ZacksCan Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory a
- BioPharma DiveNxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily Bio
- BioPharma DiveAlnylam reaches new highs on strong sales of closely watched rare disease drug This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily B